(Q34452186)

2 August 2017

0 references

Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis (English)

1 reference

2 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25478720%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Maria Ida Rizzo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25478720%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Anders Mellemgaard

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25478720%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Kyle Fahrbach

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25478720%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Alison Martin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25478720%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Rolf Kaiser

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25478720%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Ingolf Griebsch

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25478720%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Martin Reck

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25478720%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

English

0 references

publication date

5 December 2014

1 reference

2 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25478720%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25478720%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25478720%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

409-420

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25478720%20AND%20SRC:MED&resulttype=core&format=json

Management of non-small-cell lung cancer: recent developments

10 June 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.290

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.290

The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.290

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.290

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.290

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.290

Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.290

Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.290

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.290

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.290

Epidermal growth factor receptor mutations: effect on volume doubling time of non-small-cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.290

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.290

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.290

Simultaneous comparison of multiple treatments: combining direct and indirect evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.290

Combination of direct and indirect evidence in mixed treatment comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.290

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.290

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.290

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.290

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.290

Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.290

A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.290

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.290

Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.290

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.290

21 January 2018

Identifiers

DOI

10.2217/FON.14.290

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25478720%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference